Amicus Therapeutics (NASDAQ:FOLD) CEO Sells $846,276.36 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 77,926 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the transaction, the chief executive officer owned 1,129,782 shares in the company, valued at $12,269,432.52. This trade represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amicus Therapeutics Stock Up 30.4%

Amicus Therapeutics stock opened at $14.20 on Friday. The stock has a 50 day moving average of $9.48 and a two-hundred day moving average of $7.82. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $14.36. The stock has a market capitalization of $4.38 billion, a price-to-earnings ratio of -354.81 and a beta of 0.46. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The business had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, research analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Trending Headlines about Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. The Goldman Sachs Group increased their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.36.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its position in shares of Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 3,358 shares during the period. EverSource Wealth Advisors LLC increased its stake in Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,677 shares in the last quarter. Strs Ohio acquired a new position in Amicus Therapeutics during the first quarter worth $30,000. ANTIPODES PARTNERS Ltd purchased a new stake in Amicus Therapeutics during the third quarter worth $31,000. Finally, Allworth Financial LP grew its holdings in Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,246 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.